 Daisy Alapat
Concepts (252)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 30 | 2025 | 3049 | 1.920 |
Why?
| | Flow Cytometry | 5 | 2018 | 478 | 0.850 |
Why?
| | Immunoglobulins | 2 | 2018 | 76 | 0.680 |
Why?
| | Plasma Cells | 3 | 2025 | 239 | 0.650 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 2016 | 22 | 0.610 |
Why?
| | Bone Marrow | 7 | 2022 | 364 | 0.570 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 4 | 2025 | 125 | 0.570 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 146 | 0.550 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2024 | 603 | 0.520 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 106 | 0.520 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2016 | 59 | 0.490 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 15 | 0.480 |
Why?
| | Neoplasm, Residual | 6 | 2025 | 173 | 0.480 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.470 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.470 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 256 | 0.440 |
Why?
| | Humans | 50 | 2025 | 52483 | 0.390 |
Why?
| | Plasmacytoma | 3 | 2022 | 43 | 0.390 |
Why?
| | Cell Differentiation | 1 | 2015 | 665 | 0.380 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 11 | 0.380 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2012 | 18 | 0.380 |
Why?
| | Carcinoembryonic Antigen | 1 | 2011 | 13 | 0.360 |
Why?
| | Calcitonin | 1 | 2011 | 30 | 0.360 |
Why?
| | Antigens, CD | 1 | 2012 | 218 | 0.340 |
Why?
| | Middle Aged | 20 | 2025 | 13028 | 0.330 |
Why?
| | Prognosis | 9 | 2025 | 2099 | 0.320 |
Why?
| | Carcinoma | 1 | 2011 | 138 | 0.320 |
Why?
| | Myogenin | 1 | 2008 | 4 | 0.310 |
Why?
| | Muscle Fibers, Slow-Twitch | 1 | 2008 | 12 | 0.310 |
Why?
| | Muscle Fibers, Fast-Twitch | 1 | 2008 | 14 | 0.310 |
Why?
| | Paraproteinemias | 2 | 2022 | 74 | 0.290 |
Why?
| | Gene Expression Profiling | 4 | 2025 | 1105 | 0.280 |
Why?
| | Positron-Emission Tomography | 3 | 2025 | 301 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1031 | 0.270 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 77 | 0.260 |
Why?
| | Aged | 18 | 2025 | 10121 | 0.250 |
Why?
| | Female | 23 | 2025 | 28171 | 0.240 |
Why?
| | Male | 20 | 2025 | 26761 | 0.240 |
Why?
| | Treatment Outcome | 10 | 2022 | 5422 | 0.230 |
Why?
| | Pancytopenia | 3 | 2016 | 38 | 0.230 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2025 | 133 | 0.230 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2022 | 42 | 0.190 |
Why?
| | Embolization, Therapeutic | 2 | 2021 | 88 | 0.190 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2020 | 37 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2022 | 89 | 0.180 |
Why?
| | Cryosurgery | 1 | 2021 | 36 | 0.180 |
Why?
| | Chromosome Deletion | 2 | 2023 | 142 | 0.180 |
Why?
| | Skin Neoplasms | 2 | 2016 | 505 | 0.170 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 488 | 0.160 |
Why?
| | Adult | 11 | 2025 | 14161 | 0.160 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 639 | 0.160 |
Why?
| | Ploidies | 1 | 2018 | 10 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 789 | 0.140 |
Why?
| | Hematopoietic Stem Cells | 1 | 2019 | 187 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2020 | 220 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 203 | 0.140 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 98 | 0.140 |
Why?
| | Sarcoma, Myeloid | 1 | 2017 | 20 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2016 | 979 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2019 | 258 | 0.130 |
Why?
| | Amyloidosis | 2 | 2016 | 85 | 0.130 |
Why?
| | Cell Cycle | 1 | 2018 | 230 | 0.130 |
Why?
| | CA-125 Antigen | 1 | 2016 | 16 | 0.130 |
Why?
| | Registries | 3 | 2025 | 581 | 0.130 |
Why?
| | Disease Progression | 4 | 2025 | 871 | 0.130 |
Why?
| | Skin Diseases, Infectious | 1 | 2016 | 7 | 0.130 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2016 | 12 | 0.130 |
Why?
| | Anemia, Aplastic | 1 | 2016 | 11 | 0.130 |
Why?
| | Myeloproliferative Disorders | 1 | 2016 | 31 | 0.120 |
Why?
| | Electrophoresis, Capillary | 1 | 2015 | 10 | 0.120 |
Why?
| | In Situ Hybridization | 1 | 2015 | 64 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 221 | 0.120 |
Why?
| | V(D)J Recombination | 1 | 2015 | 4 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2015 | 117 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1046 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2015 | 1132 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2015 | 197 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 2022 | 113 | 0.110 |
Why?
| | Prealbumin | 1 | 2014 | 22 | 0.110 |
Why?
| | Immunoglobulin Light Chains | 1 | 2015 | 90 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 334 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2025 | 3392 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 461 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2014 | 49 | 0.110 |
Why?
| | Parvoviridae Infections | 1 | 2013 | 20 | 0.100 |
Why?
| | Parvovirus B19, Human | 1 | 2013 | 17 | 0.100 |
Why?
| | Partial Thromboplastin Time | 1 | 2012 | 13 | 0.100 |
Why?
| | Prothrombin Time | 1 | 2012 | 18 | 0.100 |
Why?
| | Retrospective Studies | 5 | 2025 | 6607 | 0.100 |
Why?
| | Afibrinogenemia | 1 | 2012 | 5 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2014 | 121 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 63 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 944 | 0.100 |
Why?
| | Plasma Exchange | 1 | 2012 | 25 | 0.100 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2012 | 18 | 0.100 |
Why?
| | Glycoproteins | 1 | 2012 | 122 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 857 | 0.100 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 8 | 0.100 |
Why?
| | Histoplasma | 1 | 2011 | 24 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2011 | 20 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2024 | 747 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 137 | 0.090 |
Why?
| | Hepatitis C | 1 | 2012 | 79 | 0.090 |
Why?
| | Histoplasmosis | 1 | 2011 | 47 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2011 | 25 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2023 | 263 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1378 | 0.080 |
Why?
| | Splenic Neoplasms | 1 | 2009 | 2 | 0.080 |
Why?
| | Gene Expression | 1 | 2012 | 618 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2011 | 116 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2009 | 86 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 95 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 84 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2023 | 1165 | 0.070 |
Why?
| | HIV Infections | 1 | 2012 | 389 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 673 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2008 | 1567 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 1 | 2008 | 153 | 0.070 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 185 | 0.070 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 87 | 0.070 |
Why?
| | Adolescent | 2 | 2025 | 6739 | 0.070 |
Why?
| | Muscle Proteins | 1 | 2008 | 321 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 34 | 0.060 |
Why?
| | Semaphorin-3A | 1 | 2004 | 2 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 94 | 0.060 |
Why?
| | Nerve Degeneration | 1 | 2004 | 24 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 14 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 49 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 50 | 0.060 |
Why?
| | ROC Curve | 1 | 2025 | 253 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1222 | 0.060 |
Why?
| | Imidazoles | 1 | 2005 | 124 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2005 | 133 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 116 | 0.050 |
Why?
| | Pyridines | 1 | 2005 | 132 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 990 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.050 |
Why?
| | Pyrimidines | 1 | 2005 | 199 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 121 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 372 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 116 | 0.050 |
Why?
| | Hippocampus | 1 | 2004 | 201 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 96 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 1201 | 0.050 |
Why?
| | Transcriptome | 1 | 2025 | 370 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 1542 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 297 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 438 | 0.050 |
Why?
| | Mediastinum | 1 | 2021 | 21 | 0.050 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 108 | 0.050 |
Why?
| | Fever | 1 | 2022 | 112 | 0.050 |
Why?
| | Neurons | 1 | 2004 | 418 | 0.050 |
Why?
| | Vincristine | 1 | 2021 | 88 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2023 | 340 | 0.050 |
Why?
| | Axilla | 1 | 2021 | 92 | 0.050 |
Why?
| | Prednisone | 1 | 2021 | 102 | 0.040 |
Why?
| | Pelvis | 1 | 2021 | 69 | 0.040 |
Why?
| | Time Factors | 2 | 2017 | 2968 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 171 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2021 | 204 | 0.040 |
Why?
| | Signal Transduction | 2 | 2004 | 1671 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2004 | 332 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 188 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 136 | 0.040 |
Why?
| | Mice | 3 | 2023 | 5949 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 241 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 481 | 0.040 |
Why?
| | False Negative Reactions | 1 | 2019 | 30 | 0.040 |
Why?
| | Hospitalization | 1 | 2024 | 736 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1470 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 43 | 0.040 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 32 | 0.040 |
Why?
| | Phosphorylation | 3 | 2005 | 528 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 57 | 0.040 |
Why?
| | Genome, Viral | 1 | 2019 | 83 | 0.040 |
Why?
| | DNA, Viral | 1 | 2019 | 137 | 0.040 |
Why?
| | Virus Diseases | 1 | 2019 | 46 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2279 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 649 | 0.040 |
Why?
| | Liver | 1 | 2022 | 1156 | 0.030 |
Why?
| | Scleromyxedema | 1 | 2016 | 4 | 0.030 |
Why?
| | Schnitzler Syndrome | 1 | 2016 | 4 | 0.030 |
Why?
| | Cryoglobulinemia | 1 | 2016 | 13 | 0.030 |
Why?
| | Xanthomatosis | 1 | 2016 | 10 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 38 | 0.030 |
Why?
| | POEMS Syndrome | 1 | 2016 | 34 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 181 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 460 | 0.030 |
Why?
| | Young Adult | 1 | 2025 | 4329 | 0.030 |
Why?
| | Animals | 3 | 2023 | 13505 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 185 | 0.030 |
Why?
| | Reed-Sternberg Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 2014 | 3 | 0.030 |
Why?
| | Karyotype | 1 | 2014 | 19 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 377 | 0.030 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2014 | 20 | 0.030 |
Why?
| | Cell Division | 2 | 2005 | 291 | 0.030 |
Why?
| | Heterozygote | 1 | 2014 | 90 | 0.030 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 45 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 1347 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 582 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 405 | 0.030 |
Why?
| | Remission Induction | 1 | 2014 | 218 | 0.030 |
Why?
| | Fibrinogen | 1 | 2012 | 34 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2012 | 64 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 1327 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 945 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 772 | 0.020 |
Why?
| | Reference Values | 1 | 2012 | 313 | 0.020 |
Why?
| | Biopsy | 1 | 2014 | 605 | 0.020 |
Why?
| | Antibodies, Fungal | 1 | 2011 | 2 | 0.020 |
Why?
| | Mycological Typing Techniques | 1 | 2011 | 3 | 0.020 |
Why?
| | Cross Reactions | 1 | 2011 | 41 | 0.020 |
Why?
| | Lung Diseases, Fungal | 1 | 2011 | 20 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2011 | 123 | 0.020 |
Why?
| | Splenectomy | 1 | 2009 | 36 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1026 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 891 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2009 | 127 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2007 | 2 | 0.020 |
Why?
| | Laparoscopy | 1 | 2009 | 180 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 83 | 0.020 |
Why?
| | Cyclosporine | 1 | 2007 | 67 | 0.020 |
Why?
| | Mice, SCID | 1 | 2007 | 182 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1546 | 0.020 |
Why?
| | Models, Animal | 1 | 2007 | 234 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 243 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 2004 | 31 | 0.010 |
Why?
| | Physical Chromosome Mapping | 1 | 2004 | 8 | 0.010 |
Why?
| | tau Proteins | 1 | 2004 | 27 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 2004 | 47 | 0.010 |
Why?
| | Epitopes | 1 | 2004 | 65 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 2004 | 36 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2004 | 65 | 0.010 |
Why?
| | Catalytic Domain | 1 | 2004 | 60 | 0.010 |
Why?
| | Cricetulus | 1 | 2004 | 104 | 0.010 |
Why?
| | Mutagenesis | 1 | 2004 | 61 | 0.010 |
Why?
| | Cricetinae | 1 | 2004 | 194 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2004 | 190 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 105 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 118 | 0.010 |
Why?
| | RNA | 1 | 2004 | 168 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 578 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 612 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 778 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2004 | 187 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 1884 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 1030 | 0.010 |
Why?
|
|
Alapat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|